Medicamen Biotech Ltd. (MEDICAM): Medicamen Biotech Share Price rises 9.33% as stock trades at Rs 312.20

Medicamen Biotech Share Price is in focus today after the stock rose 9.33% to Rs 312.20, compared with the previous close of Rs 285.55. The company’s market capitalisation stands at Rs 376.03 Cr, keeping the move relevant for investors tracking Medicamen Biotech Share Price Today and Medicamen Biotech Stock News. The latest Univest data confirms a strong share price rise, but it does not establish a company-specific catalyst behind the move.

For readers following Medicamen Biotech Share Price live, the session has been active around Rs 312.20, with the stock moving from an open of Rs 289.05 to a low of Rs 282.50 and a high of Rs 312.25. Turnover stood at Rs 0.38 Cr, which helps frame the day’s activity without changing the core point: Medicamen Biotech is rising today and has drawn attention in the Indian stock market on price action alone.

Medicamen Biotech Share Price Today: Price Action Analysis

This Medicamen Biotech Share Price update is therefore best read as a verified market move first and a fundamental review second. Univest data points to a small-cap healthcare name trading with a sharper-than-usual intraday gain, so the next watchpoints are valuation context, business quality and how the stock compares with listed peers in the pharmaceuticals and drugs industry.

Medicamen Biotech Ltd. (MEDICAM) rose to Rs 312.2 from the previous close of Rs 285.55, a move of Rs 26.65 or 9.33%. The stock opened at Rs 289.05, reached a high of Rs 312.25, recorded a low of Rs 282.5.

Medicamen Biotech Share Price Today reflects a clear intraday gain of Rs 26.65 over the previous close, with the stock last traded at Rs 312.20. The day’s low was Rs 282.50, the open was Rs 289.05 and the high touched Rs 312.25, showing that buyers stayed engaged through the move. Medicamen Biotech Stock News is therefore centred on a price rise that is visible in the market itself, even though the latest Univest figures do not establish a fresh company-specific trigger. For traders scanning Stocks in News, this is a name that has moved into the day’s Top Gainers Today conversation on price action rather than commentary. The presence of Rs 0.38 Cr turnover adds a useful liquidity reference for the move.

Medicamen Biotech Ltd. (MEDICAM) Fundamental Analysis

Medicamen Biotech Ltd. (MEDICAM) fundamental metrics show P/E 35.76x, P/B 1.43x, ROE 3.23%, ROCE 5.77%. These figures provide context only and are not a buy or sell signal.

Medicamen Biotech Ltd. has a market capitalisation of Rs 376.03 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 35.76x, P/B at 1.43x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 3.23% and ROCE of 5.77%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 7.98, book value per share of Rs 199.52, dividend yield of 0.35%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.19x, median ROE of 11.82%, median ROCE of 13.71%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Medicamen Biotech Ltd. (MEDICAM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 35.76x, which is above the benchmark median of 32.19x, a difference of +11.09%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Medicamen Biotech Ltd. (MEDICAM) has a ROE of 3.23%, which is below the benchmark median of 11.82%, a difference of -72.67%. Medicamen Biotech Ltd. (MEDICAM) has a ROCE of 5.77%, which is below the benchmark median of 13.71%, a difference of -57.91%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 35.76x compared with the displayed peer median of 37.31x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 3.23% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 5.77% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Medicamen Biotech Ltd. (MEDICAM) has a market capitalisation of Rs 376.03 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching Medicamen Biotech

• Medicamen Biotech Share Price rose 9.33% and is trading near the day’s high.
• The stock is in focus as one of the day’s notable Stocks Rising Today in healthcare.
• P/E of 35.76 and P/B of 1.43 give Medicamen Biotech Share Price a distinct valuation profile.
• ROE of 3.23% and ROCE of 5.77% keep the fundamental debate active.
• Rs 376.03 Cr market cap makes Medicamen Biotech a relatively small healthcare name on Univest.

About Medicamen Biotech

Medicamen Biotech Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company is tracked on the NSE and BSE ecosystem as a listed pharma business, and its Medicamen Biotech Share Price is followed by investors who monitor smaller healthcare companies with operating leverage and valuation sensitivity. At a market capitalisation of Rs 376.03 Cr, the company sits below many established peers in scale.

From a business perspective, Medicamen Biotech is part of an industry where investors usually look at revenue quality, product execution, margins, valuation and returns on capital. The latest Univest data places the stock in a context where its balance-sheet valuation is lower than the industry median, but its return ratios remain modest. That combination keeps Medicamen Biotech Share Price relevant for readers who want to understand how a smaller healthcare company is priced relative to the broader pharmaceutical universe.

Frequently Asked Questions

Why is Medicamen Biotech Share Price rising today?

Ans. Medicamen Biotech Share Price rose 9.33% to Rs 312.20, but the latest Univest data does not establish a company-specific catalyst. The move is confirmed by price action, previous close and intraday range.

What is Medicamen Biotech Share Price Today?

Ans. Medicamen Biotech Share Price Today is Rs 312.20, up Rs 26.65 from the previous close of Rs 285.55. The stock also touched Rs 312.25 during the day, keeping attention on its intraday strength.

What is the market capitalisation of Medicamen Biotech?

Ans. Medicamen Biotech has a market capitalisation of Rs 376.03 Cr. That places it below the same-industry median of Rs 715.6 Cr, so it remains a relatively small healthcare company in the listed universe.

How does Medicamen Biotech compare with pharma peers?

Ans. Medicamen Biotech Share Price is paired with lower return ratios than listed peers such as Sun Pharmaceutical, Zydus Lifesciences and Cipla. Its P/B is also lower, while its P/E sits near the industry median.

What do Medicamen Biotech fundamentals show?

Ans. Medicamen Biotech’s fundamentals show P/E of 35.76, P/B of 1.43, ROE of 3.23%, ROCE of 5.77%, EPS of Rs 7.98 and book value of Rs 199.52. These figures give valuation context to the share price.

Is Medicamen Biotech expensive or inexpensive versus the sector?

Ans. Medicamen Biotech Share Price trades on a P/E above the industry median but a P/B below the industry median. That makes the valuation mixed rather than clearly expensive or inexpensive on one measure alone.

What does the dividend yield mean for Medicamen Biotech?

Ans. Medicamen Biotech reports a dividend yield of 0.35%. Dividend yield reflects the historical payout relative to the current share price, so it is a context measure rather than a guaranteed future payout.

Should investors track Medicamen Biotech Share Price on Univest?

Ans. Yes, investors tracking Medicamen Biotech Share Price on Univest can monitor live price movement, valuation ratios, market cap and sector context in one place. It is useful for following news flow and peer comparison.

Track Medicamen Biotech Share Price on Univest

Use Medicamen Biotech Ltd. (MEDICAM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Track Medicamen Biotech Share Price on Univest to follow live price movement, share price update coverage, fundamental ratios, market cap, 52-week levels and broader stock news in one place. Univest also helps readers compare the company with sector peers and monitor Medicamen Biotech Stock News as the market updates.